The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Shares in chipmaker Advanced Micro Devices (AMD) had also slumped in after-hours trading, falling nearly 9% before market open on Wednesday. While AMD (AMD) delivered strong fourth quarter ...

U.S. stock futures point lower as investors evaluate disappointing tech earnings, shares of Alphabet drop as the Google ...

China announced on Tuesday that it was launching an anti-trust probe into Google on Tuesday, just moments after trade tariffs ...